Evidence map›Paper›PMID 32157936›Full record

ArticleLeukemia & lymphoma2020

Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.

Prajwal Dhakal, Elizabeth Lyden, Kate-Lynn E Muir, Zaid S Al-Kadhimi, Thuy Koll, Lori J Maness, Krishna Gundabolu, Vijaya Raj Bhatt

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Optimizing management of acute leukemia in community centers and when to refer.Hematology. American Society of Hematology. Education Program · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Prajwal DhakalDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-2368-1510
Elizabeth LydenDepartment of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
Kate-Lynn E MuirDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Zaid S Al-KadhimiDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Thuy KollDepartment of Internal Medicine, Division of Geriatrics and Gerontology, University of Nebraska Medical Center, Omaha, NE, USA.
Lori J ManessDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Krishna GundaboluDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Vijaya Raj BhattDepartment of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHANG, YING · 2016 to 2025
$42.8M
An Expanded Framework to Measure Cognitive Function in Older Adults Undergoing Hematopoietic Cell TransplantationR03AG060095 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOLL, THUY · 2019 to 2020
$229k
NCI NIH HHS P30 CA036727NIA NIH HHS R03 AG060095NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

Polypharmacy, usually defined as taking ≥5 prescribed medications, increases chances of drug-drug interactions and toxicities, and may harm cancer patients who need multiple chemotherapeutic agents and supportive medications. We analyzed the effects of polypharmacy in overall survival (OS) in acute myeloid leukemia (AML). A total of 399 patients were divided into two groups: patients with polypharmacy (≥5 medications) versus without polypharmacy (<5 medications). Polypharmacy was associated with age ≥60 years, Karnofsky Performance Status of ≤80, hematopoietic cell transplant (HCT) comorbidity index of ≥5, and adverse cytogenetics. Patients with polypharmacy were less likely to receive intensity chemotherapy or HCT. One-year OS of patients with polypharmacy versus those without polypharmacy was 29 vs. 49% (

Indexed as

Antineoplastic AgentsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAgedHumansMiddle AgedPolypharmacyPrevalenceRetrospective StudiesAntineoplastic AgentsAcute myeloid leukemiamedicationsoverall survivalpolypharmacyprognosis

Identifiers

PMID32157936
PMCPMC9393046
OpenAlexW3010858519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.